<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749411</url>
  </required_header>
  <id_info>
    <org_study_id>DB1111581</org_study_id>
    <nct_id>NCT00749411</nct_id>
    <nct_alias>NCT00843206</nct_alias>
  </id_info>
  <brief_title>Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Repeat Inhaled Doses of the Combination of GSK233705 and GW642444 Administered Once-daily in Subjects With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the evaluate the safety and tolerability of repeat dosing of the
      combination of inhaled GSK233705 and GW642444 administered once-daily in subjects with COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline (Day 1) in weighted mean pulse rate over (0-4hours) at Day 28.</measure>
    <time_frame>Day 1 and 28</time_frame>
    <description>Least Square Mean Change analyses change from baseline. Baseline is the most recent result taken on or before pre-dose Day 1. The analysis of the primary endpoint was performed using a Repeated Measures Model. This model used all available weighted mean pulse rate values recorded on nominal clinic Days 1, 14 and 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weighted mean systolic blood pressure over 0-4 hours post-dose on Days 1, 14, and 28</measure>
    <time_frame>Days 1, 14 and 28</time_frame>
    <description>The weighted mean systolic blood pressure is denoted by values of Least Square Mean Change to show the change from baseline (in systolic blood pressure) on day 14 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in maximum systolic blood pressure over 0-4 hours post-dose on Days 1, 14, and 28</measure>
    <time_frame>Days 1,14 and 28</time_frame>
    <description>The baseline is the most recent result (maximum systolic blood pressure) taken on or before pre-dose 1, it is denoted by Least Square Mean Change values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change fro baseline in weighted mean diastolic blood pressure over 0-4 hours post-dose on Days 1, 14, and 28</measure>
    <time_frame>Days 1, 14 and 28</time_frame>
    <description>The weighted mean diastolic blood pressure was analyzed using a Repeated Measures Model. Values of Least Square Mean Change denote the change from baseline on day 14 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in maximum diastolic blood pressure over 0-4 hours post-dose on Days 1, 14, and 28</measure>
    <time_frame>Days 1,14 and 28</time_frame>
    <description>The maximum diastolic blood pressure was analyzed using a Repeated Measures Model. Values of Least Square Mean Change denote the change from baseline on day 14 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weighted mean plasma glucose over 0-4 hrs post-dose on Days 1, 14 and 28</measure>
    <time_frame>Days 1, 14 and 28</time_frame>
    <description>The weighted mean plasma glucose was analyzed using a Repeated Measures Model. Values of Least Square Mean Change denote the change from baseline on day 14 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in maximum plasma glucose over 0-4 hrs post-dose on Days 1, 14 and 28</measure>
    <time_frame>Day 1,14 and 28</time_frame>
    <description>The maximum plasma glucose was analyzed using a Repeated Measures Model. Values of Least Square Mean Change denote the change from baseline on day 14 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weighted mean serum potassium over 0-4 hrs post-dose on Days 1, 14, and 28</measure>
    <time_frame>Days 1, 14 and 28</time_frame>
    <description>The weighted mean serum potassium was analyzed using a Repeated Measures Model. Values of Least Square Mean Change denote the change from baseline on day 14 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in maximum serum potassium over 0-4 hrs post-dose on Days 1, 14, and 28</measure>
    <time_frame>Day 1, 14 and 28</time_frame>
    <description>The maximum serum potassium was analyzed using a Repeated Measures Model. Values of Least Square Mean Change denote the change from baseline on day 14 and 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted mean QTc interval corrected by Fridericia's method (F) over 0-4 hrs post-dose on Days 1, 14 and 28.</measure>
    <time_frame>Days 1, 14 and 28</time_frame>
    <description>Participants were monitored for 28 days. The QTcF values were taken on day 14 and 28 to analyze the change from baseline (Day 1). There was no statistical evidence of a difference at Day 1, 14 and 28 in weighted mean QTcF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted mean QTc interval corrected by Bazett's method (B) over 0-4 hrs post-dose on Days 1, 14 and 28.</measure>
    <time_frame>Days 1, 14 and 28</time_frame>
    <description>Participants were monitored for 28 days. The QTcB values were taken on day 14 and 28 to analyze the change from baseline (Day 1). There was no statistical evidence of a difference at Day 1, 14 and 28 in weighted mean QTcB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum QTc interval corrected by Fridericia's method (F) over 0-4 hrs post-dose on Days 1, 14 and 28.</measure>
    <time_frame>Day 1, 14 and 28</time_frame>
    <description>Participants were monitored for 28 days. The QTcF values were taken on day 14 and 28 to analyze the change from baseline (Day 1). There was no statistical evidence of a difference at Day 1, 14 and 28 in maximum QTcF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum QTc interval corrected by Bazett's method (B) over 0-4 hrs post-dose on Days 1, 14 and 28.</measure>
    <time_frame>Days 1, 14 and 28</time_frame>
    <description>Participants were monitored for 28 days. The QTcB values were taken on day 14 and 28 to analyze the change from baseline (Day 1). There was no statistical evidence of a difference at Day 1, 14 and 28 in maximum QTcB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premature ventricular beats, premature supraventricular beats and ventricular runs derived from 3-lead 24-hour Holter ECG monitoring at screening and Day 28</measure>
    <time_frame>Screening, Day 28</time_frame>
    <description>The premature ventricular (PVE) and supraventricular ectopic (SPVE) per participant were recorded on screening and day 28. No abnormal ventricular runs were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline from post dose Trough Force Expiratory Volume 1 (FEV1) on Days 2, 14, 28 and 29</measure>
    <time_frame>Days 2, 14, 28 and 29</time_frame>
    <description>Treatment with GSK233705/GW642444 resulted in an increase in mean serial Forced Expiratory Volume 1 (FEV1) values, they were obtained at 30 minutes and 1 hour post-dose using spirometer on visit 2,5 and 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose FEV1 (at 30 and 60 min) on Days 1, 14 and 28</measure>
    <time_frame>Days 1, 14 and 28</time_frame>
    <description>Post dose FEV1 was measured using spirometer at visit 2, 5 and 6. Participant receiving treatment of GSK233705+GW642444 resulted in an increase in mean serial FEV1 values obtained 30 minutes and 1 hour post-dose, while the participants receiving placebo have shown progressive decrease in FEV1 values from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs) and serious adverse events (SAEs) over period</measure>
    <time_frame>Up to 37 days</time_frame>
    <description>One serious adverse events (SAE) of chronic obstructive pulmonary disease is reported pre-treatment. The participant could not be classified under an arm since the adverse event (AE) occurred before treatment. Only on treatment adverse event are presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK233705/GW642444</intervention_name>
    <description>The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and females 40 to 80 years of age (inclusive)

          -  COPD diagnosis

          -  Current or previous smokers with a cigarette smoking history of at least 10 pack-

          -  Post-albuterol FEV1/FVC of 0.70 or less

          -  Post-albuterol FEV1 of 35% to 80% (inclusive)

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  current diagnosis of asthma

          -  respiratory disorders other than COPD

          -  clinically significant cardiovascular, neurological, psychiatric, renal,
             immunological, endocrine, or hematological abnormalities that are uncontrolled

          -  clinically significant sleep apnea

          -  previous lung resection surgery

          -  clinically significant abnormalities confirmed by chest x-ray that are not related to
             COPD

          -  hospitalization for COPD within 3 months of screening

          -  use of antibiotics for lower respiratory tract infection within 6 months of screening

          -  abnormal and clinically significant 12-lead ECG findings

          -  current malignancy in remission for less that 5 years

          -  medical conditions that would contraindicate the use of anticholinergics

          -  positive hepatitis B or C test

          -  history of alcohol or drug abuse

          -  unable to withhold albuterol for 6 or more hours

          -  use of long term oxygen therapy

          -  conditions that would limit the validity of informed consent

          -  use of GW642444 or GSK233705 in previous studies

          -  use of an investigation drug with 30 days of screening

          -  use of inhaled corticosteroids (ICS) at a dose greater than 1000mcg of fluticasone
             propionate or equivalent

          -  hypersensitivity to beta-agonists

          -  concurrent use of long-acting beta-agonists (LABA) or long-acting muscaring
             antagonists, LABA/ICS combination products, cytochrome p450 inhibitors, oral or depot
             corticosteroids, theophyllines, oral beta agonists, oral leukotrine modulators,
             inhaled short acting anticholinergics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Biddeford</city>
        <state>Maine</state>
        <zip>04005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>GSK has submitted manuscripts of these study results to peer-reviewed scientific journals which were not accepted for publication. GSK is providing the attached study results summary with a conclusion.</citation>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2008</study_first_submitted>
  <study_first_submitted_qc>September 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <disposition_first_submitted>February 5, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 5, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 10, 2010</disposition_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>long-acting beta agonist</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Chronic Bronchitis</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <keyword>bronchodilator</keyword>
  <keyword>long acting muscarinic antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscarinic Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>DB1111581</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>DB1111581</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>DB1111581</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>DB1111581</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>DB1111581</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>DB1111581</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>DB1111581</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <pending_results>
    <submitted>May 2, 2017</submitted>
    <returned>June 1, 2017</returned>
    <submitted>July 28, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>August 1, 2017</submitted>
    <returned>August 3, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

